Simultaneously published in JAMA Cardiology along with moderated posters at AHA, acoramidis demonstrated:59% risk reduction in ACM in the ...
Proof-of-concept trials confirm robust anti-clotting effects for Regeneron’s two mechanistically-distinct antibodies against factor XI, in patients undergoing total knee replacement Trial results cons ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback